Alnylam Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNY research report →
Companywww.alnylam.com
Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- CEO
- Yvonne L. Greenstreet
- IPO
- 2004
- Employees
- 2,230
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $39.85B
- P/E
- 68.72
- P/S
- 9.30
- P/B
- 36.89
- EV/EBITDA
- 64.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 80.89%
- Op Margin
- 17.54%
- Net Margin
- 13.46%
- ROE
- 98.29%
- ROIC
- 19.66%
Growth & Income
- Revenue
- $3.71B · 65.19%
- Net Income
- $313.75M · 212.79%
- EPS
- $2.39 · 209.63%
- Op Income
- $501.58M
- FCF YoY
- 1192.73%
Performance & Tape
- 52W High
- $495.55
- 52W Low
- $284.19
- 50D MA
- $311.59
- 200D MA
- $390.20
- Beta
- 0.30
- Avg Volume
- 1.11M
Get TickerSpark's AI analysis on ALNY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | SCHULMAN AMY W | other | 11,250 |
| May 13, 26 | SCHULMAN AMY W | other | 11,250 |
| Apr 2, 26 | McLaughlin Melissa | sell | 265 |
| Apr 2, 26 | McLaughlin Melissa | sell | 359 |
| Apr 2, 26 | McLaughlin Melissa | sell | 209 |
| Apr 2, 26 | McLaughlin Melissa | sell | 86 |
| Apr 2, 26 | McLaughlin Melissa | sell | 147 |
| Apr 2, 26 | McLaughlin Melissa | sell | 224 |
| Apr 2, 26 | McLaughlin Melissa | sell | 245 |
| Apr 2, 26 | McLaughlin Melissa | sell | 81 |
Our ALNY Coverage
We haven't published any research on ALNY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALNY Report →